SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, today announced company highlights and financial results for the second quarter ended June 30, 2015.
“Since the beginning of the second quarter of 2015, we have continued to make important strides toward our goal of becoming a leading precision oncology biotechnology company that can provide compelling treatment options to cancer patients with unmet needs,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Help employers find you! Check out all the jobs and post your resume.
“Since the beginning of the second quarter of 2015, we have continued to make important strides toward our goal of becoming a leading precision oncology biotechnology company that can provide compelling treatment options to cancer patients with unmet needs,” said Jonathan Lim, M.D., Chairman and CEO of Ignyta.
Help employers find you! Check out all the jobs and post your resume.
